Clin Oncol | Volume 4, Issue 1 | Case Report | Open Access

Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Non-Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects

Alexandru C Grigorescu1* and Teodorescu Laura Mihaela2

1Department of Medical Oncology, The Oncological Institute of Bucharest, Romania
2V Babes Diagnostic and Treatment Center, Romania

*Correspondance to: Alexandru C Grigorescu 

Fulltext PDF

Abstract

Tyrosine Kinase Inhibitors are new drugs developed in the last decade. For Non-Small Cell Lung Cancer this drug brought more hope for patients with this disease. Also TKIs are better tolerated then chemotherapy. The efficacy of TKIs is dependent of the presence of Epidermal Grows Factor Receptor gene mutation. This mutation account for about 9% of patients with lung cancer in Europe. This short review try to give the minimal knowledge to clinicians, especially medical oncologists, about mechanism of action, pharmacokinetics of TKIs used in the treatment NSCLC.

Keywords:

Tyrosine Kinase Inhibitors (TKI); Non-small cell lung cancer; Pharmacokinetics aspects

Citation:

Grigorescu AC, Mihaela TL. Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Non-Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects. Clin Oncol. 2019;4:1676.

Subscribe to Our Newsletter